Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.
|Articles|December 1, 2012
- Pharmaceutical Executive-12-01-2012
- Volume 0
- Issue 0
Top Medical Innovations for 2013
Author(s)Ben Comer
Ben Comer profiles 10 innovative technologies designated as new and revolutionary tools for the treatment of disease and disability.
Advertisement
At the conclusion of the Cleveland Clinic's Medical Innovations Summit each year, 10 innovative technologies are unveiled before the audience, and designated as new and revolutionary tools for the treatment of disease and disability. Selections for the Top 10 are chosen by way of a process that includes personal interviews with over 100 senior Cleveland Clinic physicians. Here are a few of the technologies that made the cut for 2013.
Articles in this issue
almost 14 years ago
Pharmaceutical Executive Digital Edition - December 2012almost 14 years ago
Obamacare, Innovation and Pricingalmost 14 years ago
Germany's Price Reform Revolutionalmost 14 years ago
Transforming Drug Development: A Lilly–Covance Case Studyalmost 14 years ago
The Puzzle Master: EMA's Guido RasiAdvertisement
Related to this article
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.
As leaders, we must evaluate solutions to fragmentation by asking
the right questions.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
The Battle to Own the GLP-1 Patient Journey
3
Pharmaceutical Executive Daily: FDA Approves Fayuvi
4
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
5